教室の紹介

46th Annual Meeting of American Society of Clinical Oncology

Chicago, USA, 2010. 6. 8

Impact of imatinib plus best supportive care in imatinib and sunitinib exposed patients with refractory advanced gastrointestinal stromal tumor.

Sawaki A, Kanda T, Komatsu Y, Nishida T

Phase II trial of nilotinib as third-line therapy for gastrointestinal stromal tumor (GIST) patients in Japan.

Nishida T, Sawaki A, Doi T, Yamada Y, Komatsu Y, Kanda T, Kakeji Y, Onozawa Y, Yamasaki M, Ohtsu A

The 8th Asian Pacific Oncology Summit

Tokyo, Japan, 2010. 3. 21

Rupture of intercostal artery aneurysm in neurofibromatosis type-1-associated GIST patient during sunitinib therapy.

Sakamoto K, Kanda T, Matsuki A, Hanyu T, Yajima K, Kosugi S, Hirota S, Hatakeyama K

Safety and efficacy of sunitinib therapy in Japanese patients with GISTs: A prospective study in a single institution.

Kanda T, Sakamoto K, Matsuki A, Ohashi R, Hirota S, Fujimori Y, Matsuda Y, Yajima K, Kosugi S, Hatakeyama K